4.5 Article

Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

Michael R. McClung et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Rheumatology

Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis

Christian Beyer et al.

ANNALS OF THE RHEUMATIC DISEASES (2013)

Review Biochemistry & Molecular Biology

WNT signaling in bone homeostasis and disease: from human mutations to treatments

Roland Baron et al.

NATURE MEDICINE (2013)

Article Medicine, General & Internal

Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia

Michael P. Whyte et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Article Rheumatology

Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression

Gisela Ruiz Heiland et al.

ANNALS OF THE RHEUMATIC DISEASES (2010)

Article Rheumatology

Radiographic Findings Following Two Years of Infliximab Therapy in Patients With Ankylosing Spondylitis

Desiree van der Heijde et al.

ARTHRITIS AND RHEUMATISM (2008)

Article Endocrinology & Metabolism

Enzyme replacement therapy for murine hypophosphatasia

Jose Luis Millan et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2008)

Article Rheumatology

A longitudinal study on an autoimmune murine model of ankylosing spondylitis

T Bárdos et al.

ANNALS OF THE RHEUMATIC DISEASES (2005)

Article Biochemistry & Molecular Biology

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

DG Winkler et al.

EMBO JOURNAL (2003)